Mary L. Staicu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mary L. Staicu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Allison Ramsey
Rochester General Hospital, Rochester, New York, USA; University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
5 shared publications- Allison Ramsey
Division of Allergy/Immunology/Rheumatology, Department of Medicine, Rochester Regional Health, Rochester, NY
3 shared publications Anne Marie Holly
Rochester Regional Health, Rochester, NY
2 shared publicationsKelly M. Conn
St. John Fisher College Wegmans School of Pharmacy, Rochester, New York, USA
2 shared publicationsAlexandra Yamshchikov
Infectious Diseases, Rochester General Hospital, Rochester, NY
1 shared publication- Andrea Baran
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
1 shared publication
Latest Publications
- Open Access
- 2 March 2023
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 5 (2) , dlad014
Penicillin-allergy delabelling resources for clinicians practicing in resource-limited settings: a full educational resource review of the grey literature
Background: The clinical and financial consequences associated with a penicillin-allergy label are increasingly evident and have garnered support from international organizations to prioritize penicillin-allergy delabelling programmes. Most settings lack access to resources including drug allergy specialists and rely on general practitioners (GPs) and pharmacists.Objectives: The aim of this scoping review was to identify and describe freely available penicillin-allergy delabelling materials to guide clinicians practising in resource-limited settings with initiative application.Methods: This scoping review searched two grey literature databases, six targeted websites and consulted content experts to identify freely available materials in the English language that provided evidence-based and actionable penicillin-allergy delabelling strategies. Study investigators ranked and voted on which screened resources should be included in the final review. Characteristics of resources were evaluated and compared.Results: Out of 1191 total citations, 6 open-access resources were included. Penicillin-allergy toolkits featuring various delabelling strategies were identified in four resources. The toolkits supported a broad range of downloadable and adaptable materials, predominantly targeted towards GPs. Patient educational materials were also provided. Another resource highlighted a point-of-care penicillin-allergy risk assessment calculator via a free mobile app that quickly and accurately identified low-risk penicillin-allergic patients. The final resource, a supplemental instructional video, presented impactful and standardized delabelling strategies that clinicians can adopt into daily practices.Conclusions: Limited penicillin-allergy delabelling materials are available in the grey literature but existing resources provide broad and diverse opportunities. Additional support from health protection agencies is critical to augment ongoing delabelling efforts.
- 2 March 2023
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 5 (2) , dlad014
Open AccessPenicillin-allergy delabelling resources for clinicians practicing in resource-limited settings: a full educational resource review of the grey literature
Background: The clinical and financial consequences associated with a penicillin-allergy label are increasingly evident and have garnered support from international organizations to prioritize penicillin-allergy delabelling programmes. Most settings lack access to resources including drug allergy specialists and rely on general practitioners (GPs) and pharmacists.Objectives: The aim of this scoping review was to identify and describe freely available penicillin-allergy delabelling materials to guide clinicians practising in resource-limited settings with initiative application.Methods: This scoping review searched two grey literature databases, six targeted websites and consulted content experts to identify freely available materials in the English language that provided evidence-based and actionable penicillin-allergy delabelling strategies. Study investigators ranked and voted on which screened resources should be included in the final review. Characteristics of resources were evaluated and compared.Results: Out of 1191 total citations, 6 open-access resources were included. Penicillin-allergy toolkits featuring various delabelling strategies were identified in four resources. The toolkits supported a broad range of downloadable and adaptable materials, predominantly targeted towards GPs. Patient educational materials were also provided. Another resource highlighted a point-of-care penicillin-allergy risk assessment calculator via a free mobile app that quickly and accurately identified low-risk penicillin-allergic patients. The final resource, a supplemental instructional video, presented impactful and standardized delabelling strategies that clinicians can adopt into daily practices.Conclusions: Limited penicillin-allergy delabelling materials are available in the grey literature but existing resources provide broad and diverse opportunities. Additional support from health protection agencies is critical to augment ongoing delabelling efforts.
- 1 April 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (4) , 1736-1737.e3
Examining the impact of a penicillin allergy skin testing brochure on inpatient perceptions: A pre-post intervention study
- 1 April 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (4) , 1736-1737.e3
Examining the impact of a penicillin allergy skin testing brochure on inpatient perceptions: A pre-post intervention study
- 1 July 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (7) , 2294-2301
Direct Challenges to Penicillin-Based Antibiotics in the Inpatient Setting
- 1 July 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (7) , 2294-2301
Direct Challenges to Penicillin-Based Antibiotics in the Inpatient Setting
- 1 April 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (4) , 1314-1315
Big Datasets in Antibiotic Allergy: What's the Story?
- 1 April 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (4) , 1314-1315
Big Datasets in Antibiotic Allergy: What's the Story?
- 1 November 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (6) , 2033-2040
The Use of Telemedicine for Penicillin Allergy Skin Testing
- 1 November 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (6) , 2033-2040
The Use of Telemedicine for Penicillin Allergy Skin Testing
- 1 July 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 119 (1) , 94-95
Prospective evaluation of electronic medical record penicillin allergy documentation at a tertiary community teaching hospital
- 1 July 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 119 (1) , 94-95
Prospective evaluation of electronic medical record penicillin allergy documentation at a tertiary community teaching hospital
- 1 July 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 119 (1) , 42-47
A survey of inpatient practitioner knowledge of penicillin allergy at 2 community teaching hospitals
- 1 July 2017
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 119 (1) , 42-47
A survey of inpatient practitioner knowledge of penicillin allergy at 2 community teaching hospitals
- 1 March 2016
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 73 (5) , 298-306
Implementation of a penicillin allergy screening tool to optimize aztreonam use
Purpose The implementation of a penicillin allergy screening tool to optimize the use of aztreonam is described. Methods This study was conducted at a 528-bed tertiary referral community teaching facility and compared the use of aztreonam in patients before and after the implementation of a multipronged intervention consisting of a penicillin allergy screening tool (PAST), education, order set decision support, and prospective review of aztreonam orders by the antimicrobial stewardship team and clinical pharmacists. Patients for whom aztreonam was prescribed at any time during their presentation to the hospital January 1–June 30, 2013 (preintervention period), and September 1, 2013–February 28, 2014 (postintervention period) were eligible for inclusion. Primary outcomes included total and inappropriate aztreonam usage. Secondary outcomes included cost avoidance and safety. Results A total of 496 aztreonam orders were reviewed. The total number of days of therapy (DOT) with aztreonam significantly decreased from 9.5 per 1,000 patient-days in the preintervention group to 4.4 per 1,000 patient-days in the postintervention group (p < 0.0001). The number of inappropriate aztreonam DOT decreased from 4.0 per 1,000 patient days to 0.8 per 1,000 patient-days (p < 0.0001). The median number of inappropriate aztreonam doses decreased significantly in the postintervention period, as did inappropriate aztreonam DOT (p < 0.0001 for both comparisons). An estimated cost avoidance of $60,000–$100,000 was realized, depending on the alternative antibiotic selected. Conclusion Implementation of the PAST and provider and pharmacist education reduced the use of aztreonam by promoting the first-line use of β-lactam alternatives.
- 1 March 2016
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 73 (5) , 298-306
Implementation of a penicillin allergy screening tool to optimize aztreonam use
Purpose The implementation of a penicillin allergy screening tool to optimize the use of aztreonam is described. Methods This study was conducted at a 528-bed tertiary referral community teaching facility and compared the use of aztreonam in patients before and after the implementation of a multipronged intervention consisting of a penicillin allergy screening tool (PAST), education, order set decision support, and prospective review of aztreonam orders by the antimicrobial stewardship team and clinical pharmacists. Patients for whom aztreonam was prescribed at any time during their presentation to the hospital January 1–June 30, 2013 (preintervention period), and September 1, 2013–February 28, 2014 (postintervention period) were eligible for inclusion. Primary outcomes included total and inappropriate aztreonam usage. Secondary outcomes included cost avoidance and safety. Results A total of 496 aztreonam orders were reviewed. The total number of days of therapy (DOT) with aztreonam significantly decreased from 9.5 per 1,000 patient-days in the preintervention group to 4.4 per 1,000 patient-days in the postintervention group (p < 0.0001). The number of inappropriate aztreonam DOT decreased from 4.0 per 1,000 patient days to 0.8 per 1,000 patient-days (p < 0.0001). The median number of inappropriate aztreonam doses decreased significantly in the postintervention period, as did inappropriate aztreonam DOT (p < 0.0001 for both comparisons). An estimated cost avoidance of $60,000–$100,000 was realized, depending on the alternative antibiotic selected. Conclusion Implementation of the PAST and provider and pharmacist education reduced the use of aztreonam by promoting the first-line use of β-lactam alternatives.